Pharma Mar, S.A. (BME:PHM)

Market Cap	1.68B +25.3%
Revenue (ttm)	221.39M +26.6%
Net Income	74.99M +187.0%
EPS	4.30 +188.7%
Shares Out	17.36M
PE Ratio	22.52
Forward PE	36.81
Dividend	0.80 (0.83%)
Ex-Dividend Date	Jun 25, 2025

Volume	18,592
Average Volume	88,579
Open	96.90
Previous Close	96.85
Day's Range	94.85 - 97.90
52-Week Range	70.10 - 102.40
Beta	0.32
RSI	61.19
Earnings Date	Apr 29, 2026

About Pharma Mar

Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments. The company offers Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata that treats soft tissue sarcoma and ovarian cancer; Zepzelca, a synthetic compound designed to...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 505
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: PHM

Financial Performance

In 2025, Pharma Mar's revenue was 221.39 million, an increase of 26.61% compared to the previous year's 174.86 million. Earnings were 74.99 million, an increase of 187.03%.